However, the SGLT2i treated cohort were less likely to develop heart failure (RR 0.44 [95% CI 0.23, 0.83] p =0.0092), CKD (RR 0.49 [95% CI 0.28, 0.86] p =0.0118) and be hospitalised for any cause (RR 0.59 [95% CI 0.46, 0.76] p 0.0001) when compared with the GLP-1 RA treated cohort
Led by scientists from the United States, Brazil, Iran, and Israel, the study highlights that while GLP-1 receptor agonists can be beneficial for individuals with hyperdopaminergia (elevated dopamine activity), they may have adverse effects on those with hypodopaminergia (reduced dopamine function)
CMR
Your fat tissue isnt sitting quietly in storage
The peptide is a five-residue chain capped with a C-terminal amide
Can I take Ashwagandha and Magnesium together